Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis

Overview

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy#ALA-PDT) to a conventional regimen for treatment of Actinic Keratosis. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

Full Title of Study: “Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis#a Randomized, Open-label Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: April 30, 2021

Detailed Description

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy#painless-PDT) to a conventional regimen for treatment of Actinic Keratosis. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

Interventions

  • Procedure: Aminolevulinic acid photodynamic therapy
    • Aminolevulinic acid photodynamic therapy

Arms, Groups and Cohorts

  • Experimental: Painless Photodynamic Therapy(P-PDT) group
    • The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
  • Active Comparator: Conventional Photodynamic Therapy(C-PDT) group
    • The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.

Clinical Trial Outcome Measures

Primary Measures

  • The clearance rate of Actinic Keratoses
    • Time Frame: six weeks after treatment
    • The change rate in lesion clearance of Actinic Keratoses at six weeks after treatment will be measured as the primary outcome

Secondary Measures

  • Pain assessment
    • Time Frame: Immediately, 1st minute, 3rd minute, 5th minute, 10th minute, 30th minute, 1hour ,2hour, 4hour, 12hour, 24hour,48hour ,72hour
    • The pain will be assessed using Vissual Analogue Scale(VAS) with a score range of 0-10.The higher the score,the greater the pain, with 0 being no pain and 10 being the most unbearable pain. Pain will be measured at different time points during and after every treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Clinical diagnosed with AK (OLSEN classification grade I, II, III), aged > 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients <18 years of age, children are excluded from this study); 2. All patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written informed consent. Patents are willing to pay for the treatment, and agreed to take a picture of the skin lesions. Exclusion Criteria:

1. Those who had ALA-PDT and any other studies that affect this study within 12 weeks ; 2. There are other facial diseases that may affect the efficacy evaluation, such as other photodermatosis; 3. Take phototoxic or photosensitizer within 8 weeks; 4. Clinical and / or pathological prove that the tumor has invaded other organs or tissues; 5. Serious immunocompromised persons; 6. scar constitution; 7. Patients are known to have skin photosensitivity, porphyria, or allergies to ALA, light or lidocaine; 8. Persons are suffering from severe internal diseases, mental and mental illness, infectious diseases or pregnant or lactating women.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Dermatology Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xiuli Wang, Director, Clinical Professor – Shanghai Dermatology Hospital
  • Overall Official(s)
    • Xiuli Wang, PHD,MD, Study Chair, Shanghai Skin Disease Hospital
  • Overall Contact(s)
    • Yunfeng Zhang, MD, 18217422425, yunfeng0519116@aliyun.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.